Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.
about
Therapeutic Drug Monitoring of Posaconazole: an UpdateCandida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsAntifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant TherapyImpact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.Relevance of timing for determination of posaconazole plasma concentrationsPosaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.Pharmacologic and clinical evaluation of posaconazole.Posaconazole: when and how? The clinician's view.Triazole antifungal agents in invasive fungal infections: a comparative review.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections.Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia.Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections.Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient VariabilityPrevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.Posaconazole tablets in real life lung transplantation: impact on exposure, drug-drug interactions and drug management in lung transplanted patients, including cystic fibrosis.Posaconazole liquid vs tablet formulation in lung transplant recipients.Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients.Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis.Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies
P2860
Q26746016-5E6A5DE7-4CF5-46D0-A066-54F4BEEEF1FEQ26863344-DD31B1E5-ACEF-403F-9441-3BB600264EB3Q27677470-D2F499C7-218B-471B-85BD-181AFB6FB28DQ28263601-8298799D-9645-4B2C-81C5-BEB455126201Q33726698-D0215D16-9ED6-4E52-9399-C62F586DCDD0Q34596750-94F5336A-DD20-4DA9-836F-0FFFABDC15A7Q35065721-352A0D76-AAB1-47DD-9BE2-68CD91B46809Q36018743-1F1A54A9-498B-4937-9114-D9EC77E5F6B4Q36364013-D03299D9-8F4A-4D47-898E-7C97C4B35E85Q37445943-6732AD07-12B7-479E-BC4E-9CBA7E5C039FQ37901534-05C8F162-1A01-4359-86AE-D6DDCCD11114Q37964703-C3982FD0-C5C9-4B12-B715-B6E4DA7FA221Q38193337-C33DE423-EBDD-450A-8025-E38A12EC2CC8Q38321383-5274BCB3-3FD7-440B-BF39-1719D4AC224AQ38784762-4BC3F3EE-6FC0-46A4-ABA6-EB2A1A692B06Q40517272-BE249D5D-D122-4DE0-81BC-258CCD522501Q41291872-EB9B9028-AC77-4905-9F50-5FEF9DD8EF8DQ41991703-98725D47-56EB-4642-8BC8-3FB72C4C18A2Q48157814-E9AC6609-39E2-4428-B185-85A40833E6F1Q48294234-60E705A1-2D0E-4311-B9BD-DAC9C249F59BQ48354018-EFD81BE1-06ED-412F-885A-6FD1003E7679Q55236793-4C30757B-E392-430B-8CB1-4D16F99BF891Q55386407-AB81DE07-33B8-4D84-9F64-160700A649E2Q57518392-ADCA6340-D5BC-4D14-B2ED-06CA5CE08B55
P2860
Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Clinical pharmacodynamics and ...... ole posaconazole: an overview.
@en
Clinical pharmacodynamics and ...... ole posaconazole: an overview.
@nl
type
label
Clinical pharmacodynamics and ...... ole posaconazole: an overview.
@en
Clinical pharmacodynamics and ...... ole posaconazole: an overview.
@nl
prefLabel
Clinical pharmacodynamics and ...... ole posaconazole: an overview.
@en
Clinical pharmacodynamics and ...... ole posaconazole: an overview.
@nl
P2860
P1476
Clinical pharmacodynamics and ...... ole posaconazole: an overview.
@en
P2860
P304
P356
10.1111/J.1365-2125.2010.03680.X
P407
P577
2010-10-01T00:00:00Z